Dark

Check out our Level2View

TRVN
TREVENA INC
stock OTC

EOD

Dec 18, 2025

0.0120USD0.000%(0.0000)3,495

Pre-market

0.00USD-100.000%(-0.01)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

09:10AM EST Trevena Announces Submission Of New Drug Application In China For OLINVYK By Its Partner Jiangsu Nhwa Pharmaceutical Benzinga

09:00AM EST Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa GlobeNewswire Inc

Jan 3, 2022

04:05PM EST Trevena to Participate in the Upcoming January Conferences GlobeNewswire Inc

Dec 13, 2021

07:22AM EST Trevena Announces Advancement Of TRV045 Into Clinical Development For Diabetic Neuropathic Pain Benzinga

07:00AM EST 3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers GlobeNewswire Inc

Nov 15, 2021

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

10:52AM EST Trevena Q3 EPS $(0.08) Beats $(0.09) Estimate Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

07:00AM EST Trevena Reports Third Quarter 2021 Results GlobeNewswire Inc

Nov 11, 2021

07:00AM EST Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the addition of Patricia Drake to its senior leadership team as Chief Commercial Officer. GlobeNewswire Inc

Nov 8, 2021

07:00AM EST Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2021, prior to the market open on Monday, November 15, 2021. GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Trevena Announces Two OLINVYK Presentations At ANESTHESIOLOGY 2021 Benzinga

07:00AM EDT Trevena Announces Two OLINVYK Presentations at GlobeNewswire Inc

Oct 4, 2021

08:10AM EDT Trevena Says On Oct. 1 Got Notification That IND Application For TRV045 Will Be Placed On Hold To Address Certain Phase 1 Study Design Elements; Says FDA Will Issue A Letter Within Next 30 Days Documenting Items That Need To Be Addressed Benzinga

Oct 1, 2021

11:13AM EDT Trevena's Return On Capital Employed Overview Benzinga

Sep 30, 2021

08:19AM EDT Trevena Inc. (TRVN) said a study results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19 disease severity and progression. RTTNews

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

07:01AM EDT Trevena Announces Results Of TRV027 Proof-of-Concept Study In COVID-19 Patients; Co. Reports '92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality' Benzinga

07:00AM EDT Trevena Announces Results of TRV027 Proof-of-Concept Study in GlobeNewswire Inc

Sep 17, 2021

07:00AM EDT Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life GlobeNewswire Inc

Sep 9, 2021

07:00AM EDT Trevena to Present at the H.C. Wainwright 23rd Annual Global GlobeNewswire Inc

Aug 30, 2021

07:05AM EDT Trevena Announces Two OLINVYK Abstracts Highlighting Safety Data Accepted At ANESTHESIOLOGY 2021 Benzinga

07:00AM EDT Trevena Announces Two OLINVYK Abstracts Highlighting GlobeNewswire Inc

Aug 25, 2021

07:00AM EDT Trevena Announces Wake Forest Baptist Health Joining GlobeNewswire Inc

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

07:39AM EDT Trevena: Q2 Earnings Insights Benzinga

07:00AM EDT Company reaffirms YE goal of 100 formulary wins GlobeNewswire Inc

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 10, 2021

07:19AM EDT Trevena Announces Publication Highlighting Risk / Benefit Analysis Of OLINVYK In Pain and Therapy Benzinga

07:00AM EDT Trevena Announces Publication Highlighting Risk / Benefit Analysis GlobeNewswire Inc

Aug 9, 2021

07:00AM EDT Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the second quarter ended June 30, 2021, prior to the market open on Thursday, August 12th, 2021. GlobeNewswire Inc

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 26, 2021

08:08AM EDT Trevena, Inc. (TRVN) on Monday said first patient has been enrolled in the ACTIV-4 Host Tissue study of the company's investigational drug TRV027, for the treatment of Covid-19. RTTNews

07:07AM EDT Trevena Enrolls First Patient In NIH-Funded ACTIV-4 Host Tissue Trial Of TRV027 For COVID-19 RTTNews

07:00AM EDT Trevena Announces First Patient Enrolled In NIH-Funded ACTIV-4 Host Tissue Trial Of TRV027 For COVID-19 Benzinga

07:00AM EDT Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the first COVID-19 patient has been enrolled in the NIH-funded ACTIV-4 Host Tissue (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial. GlobeNewswire Inc

Jul 23, 2021

07:00AM EDT Trevena Announces Two Leading Independent Proxy Advisory Firms GlobeNewswire Inc

Jul 12, 2021

07:04AM EDT Trevena Announces Publication of OLINVYK Health Economic Model in Journal of Comparative Effectiveness Research Benzinga

07:00AM EDT Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care GlobeNewswire Inc

Jul 8, 2021

07:27AM EDT Trevena Enrolls First Patient Enrolled In OLINVYK Phase 3 Trial In China In Partnership With Jiangsu Nhwa Pharma RTTNews

07:11AM EDT Trevena Announces First Patient Enrolled In OLINVYK Phase 3 Trial In China In Partnership With Jiangsu Nhwa Pharmaceutical Benzinga

07:10AM EDT Nhwa is conducting and funding this study to support NDA regulatory filing in China GlobeNewswire Inc

Jul 7, 2021

07:04AM EDT Trevena Announces Initiation of OLINVYK Respiratory Physiology Study Including Elderly / Obese Subjects Benzinga

07:00AM EDT Trevena Announces Initiation of OLINVYK Respiratory GlobeNewswire Inc

Jun 29, 2021

05:39AM EDT Trevena CEO Carrie Bourdow Reported Purchase of 56,200 Shares @ Avg Price of $1.79/Share in Form 4 Filing on Monday Benzinga

Jun 28, 2021

07:00AM EDT Trevena Added to Russell 2000, Russell GlobeNewswire Inc

Jun 16, 2021

07:30AM EDT Hit By The Pandemic, Trevena Restarts Opioid Use Disorder Program After More Than A Year Benzinga

07:03AM EDT Trevena Announces NIH Has Resumed Recruiting Patients In Proof-Of-Concept Study For TRV734 In Opioid Use Disorder Benzinga

07:00AM EDT Trevena Announces NIH Has Resumed Recruiting Patients in GlobeNewswire Inc

Jun 9, 2021

07:00AM EDT Trevena to Present at the JMP Securities Life Sciences Conference GlobeNewswire Inc

May 19, 2021

07:07AM EDT Trevena Announces Presentations Of OLINVYK Health Economic Models At ISPOR 2021 Benzinga

07:00AM EDT Trevena Announces Presentations of OLINVYK Health GlobeNewswire Inc

May 12, 2021

07:14AM EDT Trevena Announces Presentation Of OLINVYK Respiratory Safety Data In High-Risk Patients At 46th Annual ASRA Meeting Benzinga

07:00AM EDT Trevena Announces Presentation of OLINVYK Respiratory GlobeNewswire Inc

May 6, 2021

10:29AM EDT Trevena's TRV027 To Be Tested In NIH-Funded COVID-19 Trial Benzinga

07:35AM EDT Trevena Announces TRV027 Selected By NIH-Funded ACTIV Initiative For COVID-19 Trial Benzinga

07:19AM EDT Trevena Q1 EPS $(0.06), Same YoY Benzinga

07:03AM EDT Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative GlobeNewswire Inc

07:00AM EDT Trevena Reports First Quarter 2021 Results GlobeNewswire Inc

May 5, 2021

07:00AM EDT Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, prior to the market open on Thursday, May 6, 2021. GlobeNewswire Inc

Apr 29, 2021

07:00AM EDT Trevena, Inc. to Participate at the Sachs Associates 4th Annual GlobeNewswire Inc

Apr 21, 2021

07:55AM EDT Trevena's TRV027 Included In Global COVID-19 Study Benzinga

07:04AM EDT Trevena Announces TRV027 Selected For Inclusion In Study In Global REMAP-CAP Trial In COVID-19 Patients Benzinga

07:00AM EDT Trevena Announces TRV027 Selected for Study in Global REMAP-CAP GlobeNewswire Inc

Apr 15, 2021

07:30AM EDT Trevena, Inc. Announces Presentations of OLINVYK GlobeNewswire Inc

Mar 18, 2021

07:00AM EDT Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Marvin H. Johnson, Jr. has been appointed to the Companys Board of Directors, and will stand for election at the 2021 Annual Meeting of Stockholders. GlobeNewswire Inc

Mar 15, 2021

11:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2021 Benzinga

07:16AM EDT Oppenheimer Initiates Coverage On Trevena with Perform Rating Benzinga

Mar 9, 2021

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

09:16AM EST Trevena Q4 EPS $(0.08) Misses $(0.06) Estimate, Sales $69.00K Miss $220.00K Estimate Benzinga

07:00AM EST Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results GlobeNewswire Inc

04:09AM EST Earnings Scheduled For March 9, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 5, 2021

07:00AM EST Trevena to Release Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Mar 1, 2021

07:00AM EST Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences in March. Additional details are below: GlobeNewswire Inc

Feb 22, 2021

07:00AM EST Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST. GlobeNewswire Inc

Jan 28, 2021

07:17AM EST Trevena Highlights Publication Of OLINVYK Respiratory Safety Data In High-Risk Patients In Pain & Therapy Benzinga

07:00AM EST Trevena, Inc. Announces Publication Highlighting GlobeNewswire Inc

Jan 7, 2021

07:00AM EST Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences, with additional details below. GlobeNewswire Inc

Jan 6, 2021

07:17AM EST Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK Benzinga

07:00AM EST Trevena, Inc. Provides Update on Commercial Launch Activities for GlobeNewswire Inc

Dec 10, 2020

08:44AM EST Trevena Highlights Presentations On Novel S1P1 Receptor Modulator At American College Of Neuropsychopharmacology Annual Meeting Benzinga

08:43AM EST Trevena, Inc. Announces Presentations Highlighting Novel S1P1 GlobeNewswire Inc

Nov 20, 2020

07:06AM EST Trevena Highlights Publication Of Gastrointestinal Tolerability Profile Of Its OLINVYK Injection In Pain And Therapy Benzinga

07:00AM EST Trevena, Inc. Announces Publication Highlighting GI Tolerability GlobeNewswire Inc

Nov 9, 2020

07:00AM EST Trevena, Inc. to Participate in the Following November Virtual GlobeNewswire Inc

Nov 2, 2020

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

Oct 30, 2020

07:46AM EDT Trevena, Inc. Announces DEA Has Classified OLINVYK (oliceridine) Injection As A Schedule II Controlled Substance; Co. Expects To Make OLINVYK Available For Distribution In November Benzinga

07:44AM EDT Trevena, Inc. Announces DEA Scheduling of GlobeNewswire Inc

Oct 5, 2020

07:00AM EDT Trevena, Inc. Announces Three OLINVYK GlobeNewswire Inc

Sep 14, 2020

10:33AM EDT Benzinga's Top Upgrades, Downgrades For September 14, 2020 Benzinga

Aug 28, 2020

10:16AM EDT Benzinga's Top Upgrades, Downgrades For August 28, 2020 Benzinga

Aug 10, 2020

02:32PM EDT Mid-Afternoon Market Update: Dow Surges 300 Points; Omeros Shares Spike Higher Benzinga

12:20PM EDT Mid-Day Market Update: Crude Oil Rises 2%; Eastman Kodak Shares Plummet Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Mostly Higher; Marriott Misses Q2 Expectations Benzinga

Aug 7, 2020

10:12AM EDT Mid-Morning Market Update: Markets Open Lower; US Unemployment Rate Drops To 10.2% Benzinga

Share